Abstract
Background: Obese asthma is a complex syndrome with certain phenotypes that differ in children and adults. There is no clear evidence regarding the presence of additive or synergistic pathological interaction between obesity and asthma in children. Objectives: Our aim was to demonstrate the interaction of obesity and asthma in children in terms of airway and systemic inflammation by a controlled observational study. Methods: Four groups were formed: asthma obese (AO), asthma nonobese (ANO), non-AO (NAO), nonasthma nonobese (NANO). Spirometry test, fractional exhaled nitric oxide (FeNO) test, skin prick test, serum inflammatory biomarkers (C-reactive protein, C3, C4, adiponectin, leptin, resistin, periostin, YKL-40, Type 1, and Type 2 cytokines) were conducted and evaluated in all participants. Sputum inflammatory cells (sputum eosinophils and neutrophils) were evaluated in patients who could produce induced sputum and obesity-asthma interactions were determined. Results: A total of 153 participants aged 6–18 years were included in the study, including the AO group (n = 46), the ANO group (n = 45), the NAO group (n = 30), and the NANO group (n = 32). IL-4 (p < 0.001), IL-5 (p < 0.001), IL-13 (p < 0.001), resistin (p < 0.001), and YKL-40 (p < 0.001) levels were higher in patients with asthma independent of obesity. The lowest adiponectin level was found in the AO group and obesity-asthma interaction was detected (p < 0.001). Sputum eosinophilia (p < 0.01), sputum neutrophilia (p < 0.01), and FeNO levels (p = 0.07) were higher in asthmatic patients independent of obesity. In the group with paucigranulocytic inflammation, resistin and YKL-40 levels were significantly lower than in the group without paucigranulocytic inflammation (p < 0.01). Conclusion: No interaction was found between obesity and asthma in terms of airway inflammation. Interaction between obesity and asthma was shown in terms of adiponectin level and resistin/adiponectin and leptin/adiponectin ratios. It was found that serum YKL-40 and resistin levels could be associated with airway inflammation.
References
1.
Brewis
A
, SturtzSreetharan
C
, Wutich
A
. Obesity stigma as a globalizing health challenge
. Global Health
. 2018
;14
(1
):20
. .2.
Peters
U
, Dixon
AE
, Forno
E
. Obesity and asthma
. J Allergy Clin Immunol
. 2018 Apr
;141
(4
):1169
–79
. .3.
Vijayakanthi
N
, Greally
JM
, Rastogi
D
. Pediatric obesity-related asthma: the role of metabolic dysregulation
. Pediatrics
. 2016 May
;137
(5
):e20150812
. .4.
Ouchi
N
, Parker
JL
, Lugus
JJ
, Walsh
K
. Adipokines in inflammation and metabolic disease
. Nat Rev Immunol
. 2011 Feb
;11
(2
):85
–97
. .5.
Fantuzzi
G
. Adipose tissue, adipokines, and inflammation
. J Allergy Clin Immunol
. 2005 May
;115
(5
):911
–20
. .6.
Jensen
ME
, Collins
CE
, Gibson
PG
, Wood
LG
. The obesity phenotype in children with asthma
. Paediatr Respir Rev
. 2011
;12
(3
):152
–9
. .7.
Miethe
S
, Guarino
M
, Alhamdan
F
, Simon
HU
, Renz
H
, Dufour
JF
, Effects of obesity on asthma: immunometabolic links
. Pol Arch Intern Med
. 2018
;128
(7–8
):469
–77
. .8.
Neyzi
O
, Günöz
H
, Furman
A
, Bundak
R
, Gökçay
G
, Darendeliler
F
, Türk çocuklarında vücut ağırlığı, boy uzunluğu, baş çevresi ve vücut kitle indeksi referans değerleri
. Çocuk Sağlığı ve Hastalıkları Dergisi.
2008 Oct–Mar
;51
(1
):1
–14
.9.
Liu
AH
, Zeiger
R
, Sorkness
C
, Mahr
T
, Ostrom
N
, Burgess
S
, Development and cross-sectional validation of the childhood asthma control test
. J Allergy Clin Immunol
. 2007 Apr
;119
(4
):817
–25
. .10.
Global Initiative for Asthma
. Global strategy for asthma management and prevention
. 2020
. Available from: www.ginasthma.org.11.
Miller
MR
, Crapo
R
, Hankinson
J
, Brusasco
V
, Burgos
F
, Casaburi
R
, General considerations for lung function testing
. Eur Respir J
. 2005 Apr
;26
(1
):153
–61
. .12.
Jung
KY
, Cho
SY
, Kim
HJ
, Kim
SB
, Song
IH
. Nonalcoholic steatohepatitis associated with metabolic syndrome: relationship to insulin resistance and liver histology
. J Clin Gastroenterol
. 2014
;48
(10
):883
–8
. .13.
Paggiaro
PL
, Chanez
P
, Holz
O
, Ind
PW
, Djukanović
R
, Maestrelli
P
, Sputum induction
. Eur Respir J Suppl
. 2002 Apr
;37
(Suppl 37
):3s
–8s
.14.
Pavord
ID
, Pizzichini
MM
, Pizzichini
E
, Hargreave
FE
. The use of induced sputum to investigate airway inflammation
. Thorax
. 1997
;52
(6
):498
–501
. .15.
Hastie
AT
, Moore
WC
, Li
H
, Rector
BM
, Ortega
VE
, Pascual
RM
, Biomarker surrogates do not accurately predict sputum eosinophil and neutrophil percentages in asthmatic subjects
. J Allergy Clin Immunol
. 2013 Jul
;132
(1
):72
–80
. .16.
Simpson
JL
, Scott
R
, Boyle
MJ
, Gibson
PG
. Inflammatory subtypes in asthma: assessment and identification using induced sputum
. Respirology
. 2006 Aug
;11
(1
):54
–61
. .17.
Scarpellini
E
, Tack
J
. Obesity and metabolic syndrome: an inflammatory condition
. Dig Dis
. 2012
;30
(2
):148
–53
. .18.
Hosogai
N
, Fukuhara
A
, Oshima
K
, Miyata
Y
, Tanaka
S
, Segawa
K
, Adipose tissue hypoxia in obesity and its impact on adipocytokine dysregulation
. Diabetes
. 2007 Apr
;56
(4
):901
–11
. .19.
Mancuso
P
. Obesity and lung inflammation
. J Appl Physiol
. 2010 Mar
;108
(3
):722
–8
. .20.
Fiaschi
T
. Mechanisms of adiponectin action
. Int J Mol Sci
. 2019
;20
(12
):2894
. .21.
Medoff
BD
, Okamoto
Y
, Leyton
P
, Weng
M
, Sandall
BP
, Raher
MJ
, Adiponectin deficiency increases allergic airway inflammation and pulmonary vascular remodeling
. Am J Respir Cell Mol Biol
. 2009 Jan
;41
(4
):397
–406
. .22.
Shore
SA
, Terry
RD
, Flynt
L
, Xu
A
, Hug
C
. Adiponectin attenuates allergen-induced airway inflammation and hyperresponsiveness in mice
. J Allergy Clin Immunol
. 2006 Aug
;118
(2
):389
–95
. .23.
Zhu
XL
, Qin
XQ
, Xiang
Y
, Tan
YR
, Qu
XP
, Liu
HJ
. Adipokine adiponectin is a potential protector to human bronchial epithelial cell for regulating proliferation, wound repair and apoptosis: comparison with leptin and resistin
. Peptides
. 2013
;40
:34
–41
. .24.
Matsuzawa
Y
. Adiponectin: a key player in obesity related disorders
. Curr Pharm Des
. 2010
;16
(17
):1896
–901
. .25.
Fruhbeck
G
, Catalan
V
, Rodriguez
A
, Ramirez
B
, Becerril
S
, Salvador
J
, Involvement of the leptin-adiponectin axis in inflammation and oxidative stress in the metabolic syndrome
. Sci Rep
. 2017 Jul
;7
:6619
.26.
Nadeem
A
, Chhabra
SK
, Masood
A
, Raj
HG
. Increased oxidative stress and altered levels of antioxidants in asthma
. J Allergy Clin Immunol
. 2003 Jan
;111
(1
):72
–8
. .27.
Zhu
L
, Chen
X
, Chong
L
, Kong
L
, Wen
S
, Zhang
H
, Adiponectin alleviates exacerbation of airway inflammation and oxidative stress in obesity-related asthma mice partly through AMPK signaling pathway
. Int Immunopharmacol
. 2019
;67
:396
–407
. .28.
Huang
X
, Yang
Z
. Resistin’s, obesity and insulin resistance: the continuing disconnect between rodents and humans
. J Endocrinol Invest
. 2016 Dec
;39
(6
):607
–15
. .29.
Yannakoulia
M
, Yiannakouris
N
, Blüher
S
, Matalas
AL
, Klimis-Zacas
D
, Mantzoros
CS
. Body fat mass and macronutrient intake in relation to circulating soluble leptin receptor, free leptin index, adiponectin, and resistin concentrations in healthy humans
. J Clin Endocrinol Metab
. 2003 Apr
;88
(4
):1730
–6
. .30.
Jain
SH
, Massaro
JM
, Hoffmann
U
, Rosito
GA
, Vasan
RS
, Raji
A
, Cross-sectional associations between abdominal and thoracic adipose tissue compartments and adiponectin and resistin in the Framingham Heart Study
. Diabetes Care
. 2009 May
;32
(5
):903
–8
. .31.
Amato
MC
, Pizzolanti
G
, Torregrossa
V
, Misiano
G
, Milano
S
, Giordano
C
. Visceral adiposity index (VAI) is predictive of an altered adipokine profile in patients with type 2 diabetes
. PLoS One
. 2014 Mar
;9
(3
):e91969
. .32.
Johnson
AM
, Olefsky
JM
. The origins and drivers of insulin resistance
. Cell
. 2013 Feb
;152
(4
):673
–84
. .33.
Abate
N
, Sallam
HS
, Rizzo
M
, Nikolic
D
, Obradovic
M
, Bjelogrlic
P
, Resistin: an inflammatory cytokine. Role in cardiovascular diseases, diabetes and the metabolic syndrome
. Curr Pharm Des
. 2014
;20
(31
):4961
–9
. .34.
Al Hannan
F
, Culligan
KG
. Human resistin and the RELM of Inflammation in diabesity
. Diabetol Metab Syndr
. 2015
;7
:54
. .35.
Fang
C
, Meng
Q
, Wu
H
, Eid
G
, Zhang
G
, Zhang
X
, Resistin-like molecule-β is a human airway remodelling mediator
. Eur Respir J
. 2012 Aug
;39
(2
):458
–66
. .36.
Kwak
S
, Kim
YD
, Na
HG
, Bae
CH
, Song
SY
, Choi
YS
. Resistin upregulates MUC5AC/B mucin gene expression in human airway epithelial cells
. Biochem Biophys Res Commun
. 2018 Mar
;499
(3
):655
–61
. .37.
Ballantyne
D
, Scott
H
, MacDonald-Wicks
L
, Gibson
PG
, Wood
LG
. Resistin is a predictor of asthma risk and resistin:adiponectin ratio is a negative predictor of lung function in asthma
. Clin Exp Allergy
. 2016 Apr
;46
(8
):1056
–65
. .38.
Zhu
Z
, Zheng
T
, Homer
RJ
, Kim
YK
, Chen
NY
, Cohn
L
, Acidic mammalian chitinase in asthmatic Th2 inflammation and IL-13 pathway activation
. Science
. 2004 Jun
;304
(5677
):1678
–82
. .39.
Kawada
M
, Hachiya
Y
, Arihiro
A
, Mizoguchi
E
. Role of mammalian chitinases in inflammatory conditions
. Keio J Med
. 2007 Mar
;56
(1
):21
–7
. .40.
Konradsen
JR
, James
A
, Nordlund
B
, Reinius
LE
, Söderhäll
C
, Melén
E
, The chitinase-like protein YKL-40: a possible biomarker of inflammation and airway remodeling in severe pediatric asthma
. J Allergy Clin Immunol
. 2013 Aug
;132
(2
):328
–e5
. .41.
Santos
CB
, Davidson
J
, Covar
RA
, Spahn
JD
. The chitinase-like protein YKL-40 is not a useful biomarker for severe persistent asthma in children
. Ann Allergy Asthma Immunol
. 2014
;113
(3
):263
–6
. .42.
Specjalski
K
, Jassem
E
. YKL-40 protein is a marker of asthma
. J Asthma
. 2011
;48
(8
):767
–72
. .43.
Ilmarinen
P
, Tuomisto
LE
, Niemelä
O
, Hämäläinen
M
, Moilanen
E
, Kankaanranta
H
. YKL-40 and adult-onset asthma: Elevated levels in clusters with poorest outcome
. J Allergy Clin Immunol Pract
. 2019 Sep–Oct
;7
(7
):2466
–e3
. .44.
Gomez
JL
, Yan
X
, Holm
CT
, Grant
N
, Liu
Q
, Cohn
L
, Characterisation of asthma subgroups associated with circulating YKL-40 levels
. Eur Respir J
. 2017
;50
(4
):1700800
. .45.
Specjalski
K
, Chełmińska
M
, Jassem
E
. YKL-40 protein correlates with the phenotype of asthma
. Lung
. 2015 Feb
;193
(2
):189
–94
. .46.
Liu
L
, Zhang
X
, Liu
Y
, Zhang
L
, Zheng
J
, Wang
J
, Chitinase-like protein YKL-40 correlates with inflammatory phenotypes, anti-asthma responsiveness and future exacerbations
. Respir Res
. 2019
;20
(1
):95
. .47.
Lai
T
, Chen
M
, Deng
Z
, L
Y
, Wu
D
, Li
D
, YKL-40 is correlated with FEV1 and the asthma control test (ACT) in asthmatic patients: influence of treatment
. BMC Pulm Med
. 2015
;15
:1
. .48.
Leonardi
S
, Filippelli
M
, Lanzafame
A
, Parisi
G
, Mistrello
G
, Musumeci
M
, Serum YKL-40 in children with asthma
. J Biol Regul Homeost Agents
. 2015
;29
(2 Suppl 1
):114
–9
.49.
Chen
YC
, Chih
AH
, Chen
JR
, Liou
TH
, Pan
WH
, Lee
YL
. Rapid adiposity growth increases risks of new-onset asthma and airway inflammation in children
. Int J Obes
. 2017 Mar
;41
(7
):1035
–41
. .50.
Rastogi
D
, Suzuki
M
, Greally
JM
. Differential epigenome-wide DNA methylation patterns in childhood obesity-associated asthma
. Sci Rep
. 2013 Jul
;3
:2164
. .51.
Jensen
ME
, Gibson
PG
, Collins
CE
, Wood
LG
. Airway and systemic inflammation in obese children with asthma
. Eur Respir J
. 2013 Jan
;42
(4
):1012
–9
. .© 2021 S. Karger AG, Basel
2021
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.
